Table 6.

Patients’ Characteristics And Demographic Data Between Gefitinib And Ecotinib

Characteristics			Gefitinib	Ecotinib	p-Value
Age, median (range, yr)			61(44–85)	60 (37–76)	0.265
Gender		Male	26(76.47%)	8(23.53%)	0.029
Female	34(53.97%)	29(46.03%)
Primary site		Left lung	29(67.44%)	14(32.56%)	0.281
		Right lung	31(58.49%)	22(41.51%)
Unknown	0(0.00%)	1(100.00%)
Performance status		ECOG <2	56(62.92%)	33(37.08%)	0.476
ECOG ≥ 2	4(50.00%)	4(50.00%)
EGFR mutation status before TKI		Exon 19 deletions	29(60.42%)	19(39.58%)	0.460
		Exon 21 L858R	19(70.37%)	8(29.63%)
		Other mutation	0(0.00%)	1(100.00%)
Unknown	12(57.14%)	9 (42.86%)
EGFR mutation status after TKI		Exon 19 deletion	18(50.00%)	18(50.00%)	0.248
		Exon 21 L858R	11 (61.11%)	7 (38.89%)
		No common mutation (Exon 19 deletion and Exon 21 L858R)	14 (70.00%)	6 (30.00%)
Unknown	17 (73.91%)	6 (26.09%)
PFS of initial TKI, median (range, months)			18(1–56)	16 (3–63)	0.204
Response of initial TKI		PR	19 (57.58%)	14 (42.42%)	0.643
		SD	23 (60.53%)	15 (39.47%)
Unknown	18(69.23%)	8(30.77%)
Metastasis site	Lung	Yes	52(60.47%)	34(39.53%)	0.837
		No	7(70.00%)	3(30.00%)
	Unknown	1(100.00%)	0(0.00%)
	Bone	Yes	30(63.83%)	17(36.17%)	0.802
		No	29(59.18%)	20(40.82%)
	Unknown	1(100.00%)	0(0.00%)
	Brain	Yes	22(73.33%)	8(26.67%)	0.141
		No	37(56.06%)	29(43.94%)
	Unknown	1(100.00%)	0(0.00%)
	Other	Yes	11(68.75%)	5(31.25%)	0.743
		No	48(60.00%)	32(40.00%)
Unknown	1(100.00%)	0(0.00%)
Treatment before TKI	Chemotherapy	Yes	29(59.18%)	20(40.82%)	0.852
		No	26(63.41%)	15(36.59%)
	Unknown	5(71.43%)	2(28.57%)
	Operation	Yes	8(50.00%)	8(50.00%)	0.289
		No	49(62.82%)	29(37.18%)
Unknown	3(100.00%)	0(0.00%)
Sample type of T790M		Tissue only	29 (59.18%)	20 (40.82%)	0.633
		Plasma only	28 (66.67%)	14 (33.33%)
Tissue and Plasma	3 (50.00%)	3 (50.00%)